Biotechs' financing deals help with development costs

05/8/2006 | American City Business Journals

Biotechnology companies already burdened with funding treatments nearing market approval are entering into agreements with private-equity firms to create separate entities to help shoulder the risk and cost associated with developing promising early-stage drugs. This financing mechanism fell out of favor amid some scandals involving off-balance sheet arrangements, but the new deals are transparent and the entities' financial dealings are covered in the parent company's statements.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC